"10.1371_journal.pone.0074193","plos one","2013-09-13T00:00:00Z","Pallav Bhatnagar; Emily Barron-Casella; Christopher J Bean; Jacqueline N Milton; Clinton T Baldwin; Martin H Steinberg; Michael DeBaun; James F Casella; Dan E Arking","McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Department of Pediatrics, Division of Pediatric Hematology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Clinical and Molecular Hemostasis Laboratory Branch, Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America; Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, United States of America; Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America; Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America","Conceived and designed the experiments: Participated in the conception, study design, and edited the manuscript: DEA JFC MDB MHS. Collected and prepared DNA for the GWAS, provided patient information and laboratory data for the SIT Trial cohort, and edited the manuscript: EBC. Performed stage 2 GWAS genotyping for the SIT Trial samples: CJB. Performed genotyping for the CSSCD cohort: CTB. Collected and managed the CSSCD database and genotyping results: JNM. Performed the statistical analysis: PB. Wrote the manuscript: PB DEA JFC MDB MHS.","James F. Casella has received an honorarium and travel expenses in the past and presently receives salary support through Johns Hopkins for providing consultative advice to Mast Therapeutics (previously called Adventrx Pharmaceuticals) regarding a proposed clinical trial of an agent for treating vaso-occlusive crisis in sickle cell disease. Dr. Casella is also listed as an inventor on a patent licensed to ImmunArray Corp. Biomarkers of Brain Injury (International Publication Number: WO 2012/051519) and one further pending patent. Dan Arking serves as a PLOS Editorial Board member. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","09","Pallav Bhatnagar","PB",9,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
